Liver Infarction after Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma in the Setting of a Large Portosystemic Shunt.

about

Liver Infarction after Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma in the Setting of a Large Portosystemic Shunt.

Item

http://www.wikidata.org/entity/Q39025146

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Liver Infarction after Drug-El ...... f a Large Portosystemic Shunt.

@en

Liver Infarction after Drug-El ...... f a Large Portosystemic Shunt.

@nl

type

Item

label

Liver Infarction after Drug-El ...... f a Large Portosystemic Shunt.

@en

Liver Infarction after Drug-El ...... f a Large Portosystemic Shunt.

@nl

prefLabel

Liver Infarction after Drug-El ...... f a Large Portosystemic Shunt.

@en

Liver Infarction after Drug-El ...... f a Large Portosystemic Shunt.

@nl

P1476

Liver Infarction after Drug-El ...... of a Large Portosystemic Shunt

@en

P2093

Benjamin V Park

http://www.w3.org/2001/XMLSchema#string

Ron C Gaba

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hepatocellular carcinoma: An update

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma.

Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma.

Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.

Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts.

Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt.

Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong?

P304

337-341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1055/S-0036-1592319

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

R Peter Lokken

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27904254

http://www.w3.org/2001/XMLSchema#string

P932

5088095

http://www.w3.org/2001/XMLSchema#string